Amir T. Fathi

Also affiliated with University of Michigan, Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center, Global Cancer Institute, Center for Cancer Research

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies”.

A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3790

N/A

0DataRank · unranked

11 citations

Amir T. Fathi, Ashwin Kishtagari, Kapil N. Bhalla, Alfonso Quintás‐Cardama, Sarah A. Reilly +25 more